Related Experiment Video

Updated: May 8, 2025

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin
10:15

Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin

Published on: November 1, 2019

12.3K

MicroRNAs modulation by curcumin, catalpol, and other natural products in Alzheimer's disease: a review

Amir Modarresi Chahardehi1, Reza Arefnezhad1,2, Alireza Pourbafrani3

  • 1Coenzyme R Research Institute, Tehran, Iran.

Molecular Biology Reports
|May 6, 2025
PubMed

Insights

Natural products like curcumin can modulate microRNAs (miRNAs) to combat Alzheimer's disease (AD) by targeting key pathological pathways. This review explores their neuroprotective potential and challenges for clinical use.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited treatment options.
  • MicroRNAs (miRNAs) are implicated in AD pathogenesis, affecting amyloid-beta aggregation, tau phosphorylation, neuroinflammation, and oxidative stress.

Purpose of the Study:

  • To review the impact of natural products on miRNA regulation in Alzheimer's disease.
  • To summarize the molecular targets and therapeutic potential of these natural products.
  • To discuss challenges and future directions for miRNA-based AD therapies.

Main Methods:

  • Systematic review of scientific literature.
  • Analysis of studies on natural products and their effects on miRNA expression in AD models.
  • Examination of molecular targets and mechanisms of action.

Main Results:

  • Natural products including curcumin, catalpol, Allium jesdianum, Tanshinone IIA (Tan IIA), and Tiaoxin Recipe (TXR) show potential in modulating miRNA expression relevant to AD.
  • These compounds exert neuroprotective effects through multi-target mechanisms.
  • Identified miRNAs include miR-132, miR-34a, and miR-124, which are crucial in AD pathology.

Conclusions:

  • Natural products offer a promising avenue for Alzheimer's disease therapy by modulating miRNA pathways.
  • Overcoming challenges in bioavailability and clinical translation is crucial for developing effective treatments.
  • Advanced delivery systems and personalized medicine approaches are needed for successful clinical application.
Keywords:
Allium jesdianumAlzheimer's diseaseCatalpolCurcuminMicroRNANatural productsNeuroprotectionOxidative stressTanshinone IIATiaoxin recipe

More Related Videos

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

8.9K
Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

11.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
313
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85